6533b7d2fe1ef96bd125e11a
RESEARCH PRODUCT
Acute and sustained increase in endothelial biomarkers in COVID-19.
Mónica PiquerasEnrique Zaldívar-olmedaRaúl MéndezSoledad ReyesKatheryn YépezAntonio MoscardóLeyre BouzasAna LatorrePaula González-jiménezRicardo AlonsoAna FerrandoRosario Menéndezsubject
Pulmonary and Respiratory Medicinemedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)business.industryRespiratory infectionCOVID-19Emergency departmentmedicine.diseaseIntensive care unitlaw.inventionHospitalizationPneumoniaIntensive Care UnitslawDiffusing capacityInternal medicinemedicineCardiologyHumansIn patientHospital MortalityRespiratory systembusinessBiomarkersdescription
Endothelial injury is related to poor outcomes in respiratory infections yet little is known in relation to COVID-19. Performing a longitudinal analysis (on emergency department admission and post-hospitalisation follow-up), we evaluated endothelial damage via surrogate systemic endothelial biomarkers, that is, proadrenomedullin (proADM) and proendothelin, in patients with COVID-19. Higher proADM and/or proendothelin levels at baseline were associated with the most severe episodes and intensive care unit admission when compared with ward-admitted individuals and outpatients. Elevated levels of proADM or proendothelin at day 1 were associated with in-hospital mortality. High levels maintained after discharge were associated with reduced diffusing capacity.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-12-21 | Thorax |